
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences is positioned for significant growth, with expectations for Cologuard to increase its market share from approximately 15% to over 40%, driving substantial revenue growth. The company has recently raised its 2025 guidance following a strong Q3 performance, recording a 22% year-over-year growth in its core screening business, largely attributed to advancements in Cologuard rescreens and health plan initiatives. Furthermore, Exact Sciences is generating positive adjusted EBITDA and plans to screen at least 30 million people by 2027, representing a threefold increase in screenings, which bodes well for future financial performance.
Bears say
Exact Sciences is facing challenges due to its dependency on promotional marketing efforts to drive demand for its Cologuard screening test, which raises concerns about revenue stability. The company has a history of net losses, casting doubt on its ability to achieve and maintain GAAP profitability in the future. Furthermore, despite a projected revenue estimate of $4.0 billion for 2027, this figure is still below the company's targets, highlighting ongoing financial uncertainties and potential conservative assumptions in revenue projections.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares